J.M. Forbes & Co’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $907K | Hold |
3,704
| – | – | 0.07% | 80 |
|
|
2026
Q1 | $626K | Hold |
3,704
| – | – | 0.05% | 94 |
|
|
2025
Q4 | $676K | Hold |
3,704
| – | – | 0.05% | 91 |
|
|
2025
Q3 | $450K | Hold |
3,704
| – | – | 0.04% | 107 |
|
|
2025
Q2 | $387K | Sell |
3,704
-136
| -4% | -$14.4K | 0.04% | 116 |
|
|
2025
Q1 | $448K | Hold |
3,840
| – | – | 0.04% | 105 |
|
|
2024
Q4 | $325K | Hold |
3,840
| – | – | 0.03% | 120 |
|
|
2024
Q3 | $345K | Hold |
3,840
| – | – | 0.03% | 115 |
|
|
2024
Q2 | $309K | Hold |
3,840
| – | – | 0.03% | 114 |
|
|
2024
Q1 | $306K | Hold |
3,840
| – | – | 0.03% | 114 |
|
|
2023
Q4 | $306K | Hold |
3,840
| – | – | 0.04% | 110 |
|
|
2023
Q3 | $268K | Hold |
3,840
| – | – | 0.03% | 115 |
|
|
2023
Q2 | $276K | Hold |
3,840
| – | – | 0.03% | 115 |
|
|
2023
Q1 | $237K | Hold |
3,840
| – | – | 0.03% | 102 |
|
|
2022
Q4 | $296K | Buy |
+3,840
| New | +$230K | 0.04% | 90 |
|
|
2021
Q3 | – | Sell |
-3,840
| Closed | -$259K | – | 115 |
|
|
2021
Q2 | $259K | Hold |
3,840
| – | – | 0.03% | 102 |
|
|
2021
Q1 | $217K | Hold |
3,840
| – | – | 0.03% | 98 |
|
|
2020
Q4 | $313K | Hold |
3,840
| – | – | 0.05% | 87 |
|
|
2020
Q3 | $273K | Hold |
3,840
| – | – | 0.04% | 85 |
|
|
2020
Q2 | $316K | Hold |
3,840
| – | – | 0.06% | 75 |
|
|
2020
Q1 | $226K | Hold |
3,840
| – | – | 0.05% | 80 |
|
|
2019
Q4 | $397K | Buy |
+3,840
| New | +$155K | 0.07% | 82 |
|
|
2018
Q4 | – | Sell |
-15,066
| Closed | -$52K | – | 102 |
|
|
2018
Q3 | $52K | Hold |
15,066
| – | – | 0.01% | 99 |
|
|
2018
Q2 | $48K | Hold |
15,066
| – | – | 0.01% | 101 |
|
|
2018
Q1 | $37K | Hold |
15,066
| – | – | 0.01% | 104 |
|
|
2017
Q4 | $84K | Hold |
15,066
| – | – | 0.02% | 103 |
|
|
2017
Q3 | $83K | Hold |
15,066
| – | – | 0.02% | 98 |
|
|
2017
Q2 | $82K | Hold |
15,066
| – | – | 0.02% | 99 |
|
|
2017
Q1 | $59K | Hold |
15,066
| – | – | 0.02% | 101 |
|
|
2016
Q4 | $101K | Hold |
15,066
| – | – | 0.03% | 99 |
|
|
2016
Q3 | $119K | Buy |
+15,066
| New | +$114K | 0.03% | 95 |
|
Other funds holding AXSM
DTC
J.M. Forbes & Co's AXSM Position: Q2 2026 in Review
J.M. Forbes & Co held its Axsome Therapeutics (AXSM) position steady in Q2 2026 at 3,704 shares worth $907K. The position accounts for 0.07% of the portfolio, ranked #80.
J.M. Forbes & Co first reported a position in AXSM in Q3 2016 and has held it in 31 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.
- J.M. Forbes & Co held 3,704 shares of Axsome Therapeutics worth $907K as of Q2 2026.
- J.M. Forbes & Co left its Axsome Therapeutics share count unchanged in Q2 2026.
- Axsome Therapeutics made up 0.07% of J.M. Forbes & Co's portfolio in Q2 2026, its #80 holding.
- J.M. Forbes & Co first reported a position in Axsome Therapeutics in Q3 2016 and has held it in 31 quarters since.
- 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.
Based on J.M. Forbes & Co's 13F filing for Q2 2026, filed 20 Jul 2026.